Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)
Condition: Non-small Cell Lung Cancer Intervention: Drug: DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin) Sponsor: Dizal Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Crestor | HER2 | Lung Cancer | Non-Small Cell Lung Cancer | Research | Rosuvastatin